A Phase II Evaluation of Pazopanib (NSC 737754, IND 75648) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus.

Trial Profile

A Phase II Evaluation of Pazopanib (NSC 737754, IND 75648) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus.

Completed
Phase of Trial: Phase II

Latest Information Update: 31 Aug 2017

At a glance

  • Drugs Pazopanib (Primary)
  • Indications Uterine cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 06 May 2016 Status changed from active, no longer recruiting to completed.
    • 01 Mar 2014 Interim results (n=22) published in the Gynecologic Oncology.
    • 11 Mar 2013 Planned End Date changed from 1 Feb 2014 to 1 May 2016 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top